Reconstituted HDL: A Therapy for Atherosclerosis and Beyond

Andrew J Murphy; Jaye Chin-Dusting; Dmitri Sviridov


Clin Lipidology. 2009;4(6):731-739. 

In This Article

Future Perspective

From the limited number of studies conducted to date, it would seem that the future for the use of rHDL in the clinic is promising. Discoveries in regards to the positive effects of HDL are still being made not only in CVD, but also other inflammatory diseases such as arthritis. However, prior to rHDL being routinely used in the clinic, there is still a considerable amount of research required to prove that rHDL is indeed a viable therapeutic strategy. There is a need for further understanding on the mechanisms through which rHDL functions to act as a cardioprotective drug and whether there is a requirement for rHDL to be used as a co-therapy to maximize the protective effects. The obvious use for rHDL in the clinic is to treat CVD; however, it has yet to be determined for which patient groups rHDL administration would be beneficial (i.e., only in patients with acute coronary syndrome to stabilize plaques or to a broader patient population). The role HDL appears to play in stabilizing plaques, reducing the inflammatory status of circulating cells along with the reported antiatherosclerotic effects, may suggest it could be used as a pre- or post-operative treatment to minimize risk of vascular surgery. Thus, we conclude that the future of rHDL-based therapies in the clinic is potentially broad and will successfully aid in the fight to manage CVD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.